• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Spinal muscular atrophy Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Spinal muscular atrophy.
  • The report assesses Spinal muscular atrophy pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Spinal muscular atrophy pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Spinal muscular atrophy ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Lexicon Genetics, Neurotune, PTC Therapeutics, Navinta LLC, Academia Sinica, Genzyme Corporation, Genzyme Corporation, Isis Pharmaceuticals, Neurodyn, Novartis Pharmaceuticals Corporation, Cytokinetics, RaNA Therapeutics, Voyager Therapeutics, AveXis, Bioblast Pharma, Novartis, AndroScience Corporation

Key Drugs:

Olesoxime, Sodium phenylbutyrate liquid, Nusinersen, Sodium valproate, RG 3039, BVS 857, CK 2127107, RG 7800, AVXS 101, LMI 070, RG 7916, ASC JM.X1, STL 182, Sodium phenylbutyrate, Gabapentin, ASCJ 9, Tirasemtiv, Vamorolone, Trehalose,

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8
Price:

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry





Leave a Reply

Your email address will not be published.

Contact
+91 9643310025, 9643312749
© 2019 Pharmintel